Advertisement
Advertisement
RGEN
Repligen Corp
116.65
USDSponsored
-1.66
-1.40%
May 01, 12:17 UTC -4
Open
RGEN Earnings Reports
Positive Surprise Ratio
RGEN beat 34 of 41 last estimates.
83%
Next Report
Next Week
Date of Next Report
May 05, 2026
Estimate for Q1 26 (Revenue/ EPS)
$196.12M
/$0.39
Implied change from Q4 25 (Revenue/ EPS)
-0.90%
/-20.41%
Implied change from Q1 25 (Revenue/ EPS)
+15.93%
/--
Repligen Corp earnings per share and revenue
On Feb 24, 2026, RGEN reported earnings of 0.49 USD per share (EPS) for Q4 25, beating the estimate of 0.44 USD, resulting in a 9.25% surprise. Revenue reached 197.91 million, compared to an expected 196.77 million, with a 0.58% difference. The market reacted with a -0.54% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 19 analysts forecast an EPS of 0.39 USD, with revenue projected to reach 196.12 million USD, implying an decrease of -20.41% EPS, and decrease of -0.90% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bio-Rad Laboratories, Inc. Class B
Report Date
Apr 30, 2026 For Q1 26
Estimate
$2.00
Actual
$1.89
Surprise
-5.68%
Kymera Therapeutics, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.89
Actual
-$0.71
Surprise
+21.05%
Syndax Pharmaceuticals, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.59
Actual
-$0.48
Surprise
+19.15%
Amgen Inc
Report Date
Apr 30, 2026 For Q1 26
Estimate
$4.85
Actual
$5.15
Surprise
+6.15%
Bristol-Myers Squibb Co.
Report Date
Apr 30, 2026 For Q1 26
Estimate
$1.42
Actual
$1.58
Surprise
+10.95%
Alnylam Pharmaceuticals, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
$0.95
Actual
$1.99
Surprise
+108.95%
Moderna, Inc. Common Stock
Report Date
May 01, 2026 For Q1 26
Estimate
-$3.32
Actual
-$1.18
Surprise
+64.48%
Illumina Inc
Report Date
Apr 30, 2026 For Q1 26
Estimate
$1.07
Actual
$1.14
Surprise
+6.94%
NovoCure Limited Ordinary Shares
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.52
Actual
-$0.62
Surprise
-18.52%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.32
Actual
-$0.18
Surprise
+45.22%
FAQ
What were Repligen Corp's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Repligen Corp reported EPS of $0.49, beating estimates by 9.25%, and revenue of $197.91M, 0.58% above expectations.
How did the market react to Repligen Corp's Q4 2025 earnings?
The stock price moved down -0.54%, changed from $135.40 before the earnings release to $134.67 the day after.
When is Repligen Corp expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for Repligen Corp's next earnings report?
Based on 19
analysts, Repligen Corp is expected to report EPS of $0.39 and revenue of $196.12M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement